Page 324 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

280 MEDICAMENTINDUISANTDES MODIFICATIONS COVALENTES DE L'ADN

MICHEAU O. et al., Fas ligand-independent, FADD-mediated activation of the Fas death
pathway by anticancer drugs, J. Biol. Chem., 1999, 274, 7987-7992.
GIACCONE G., Clinical perspectives on platinum resistance, Drugs, 2000, 59, 9-17.
MESE H. et al., The raie of caspase family protease, caspase-3 on cisplatin-induced
apoptosis in cisplatin-resistant A431 cell line, Cancer Chemother. Pharmacol., 2000,
46, 241-245.
KOUKOURAKIS M.I. et al., Nuclear expression of human apurinic/apyrimidinic endonu-
clease (HAP1/REF-1) in head-and-neck cancer is associated with resistance to che-
moradiotherapy and poor outcome, /nt. J. Radiation Onco/ogy Biol. Phys., 2001, 50,
27-36.
OGURI T. et al., Association between expression of the MRP3 gene and exposure to
platinum drugs in lung cancer, /nt. J. Cancer, 2001, 93, 584-589.
RELES A et al., Correlation of p53 mutations with resistance to platinum-based chemo-
therapy and shortened survival in ovarian cancer, Clin. Cancer Res., 2001, 7, 2984-
2997.
SCHUYER M. et al., Reduced expression of BAX is associated with poor prognosis in
patients with epithelial ovarian cancer : a multifactorial analysis of TP53, p21, BAX and
BCL-2, Br. J. Cancer, 2001, 85, 1359-1367.
VIKHANSKAYA F. et al., P73a overexpression is associated with resistance to treatment
with DNA-damaging agents in a human ovarian cancer cell line, Cancer Res., 2001,
61, 935-938.
PROPRIÉTÉS THÉRAPEUTIQUES, EFFETS INDÉSIRABLES
HOHNLOSER J.H. et al., Cisplatin-based chemotherapy in testicular cancer patients :
long-term platinum excretion and clinical effects, Eur. J. Med. Res., 1996, 1, 509-514.
LIEBERTHAL W. et al., Mechanisms of death induced by cisplatin in proximal tubular
epithelial cells : apoptosis vs. necrosis, Am. J. Physiol., 1996, 270, F700-F708.
ZHANG J.G., LINDUP W.E., Cisplatin-induced nephrotoxicity in vitro : increases in cyto-
solic calcium concentration and the inhibition of cytosolic and mitochondrial protein
kinase C, Toxicol. Lett., 1996, 89, 11-17.
KRONING R. et al., Differential effects of cisplatin in proximal and distal renal tubule
epithelial cell lines, Br. J. Cancer, 1999, 79, 293-299.
LAJER H., DAUGAARD G., Cisplatin and hypomagnesemia, Cancer Treat. Rev., 1999,
25, 47-58.
VIALE M. et al., Cisplatin combined with tiopronin or sodium thiosulfate : cytotoxicity
in vitro and antitumor activity in vivo, Anti-Cancer Drugs, 1999, 10, 419-428.
STOEHLMACHER J. et al., A polymorphism of the XRCC1 gene predicts for response to
platinum based treatment in advanced colorectal cancer, Anticancer Res., 2001, 21,
3075-3079.
AUTRES PRODUITS
Miboplatin, Neoplat : Drugs Fut., 1997, 22, 1167-1168.
Sebriplatin : Drugs Fut., 1997, 22, 94.
TRK-710 : Drugs Fut., 1997, 22, 38-39.